At BELLUS, we are focused on developing drugs for rare diseases starting with conditions that affect the kidneys. Read More

At BELLUS, we are focused on developing drugs for rare diseases starting with conditions that affect the kidneys. Read More

At BELLUS, we are focused on developing drugs for rare diseases starting with conditions that affect the kidneys. Read More

Blog

December 1, 2015 The Perils Of A Big Pharma Partnership
– What a Megamerger Like Pfizer and Allergan’s Can Mean to Biotech Partnerships – The media commentary around Pfizer and Allergan’s mega merger announced earlier this week has focused primarily around the fact that the deal is structured as a corporate inversion so that Pfizer can reduce its expected tax rate from 25% to 17%. While investors are sweating over whether the US government will...
Read More
October 13, 2015 Bellus Health’s Shiga Toxin Antibody ShigamabTM
– Highlighted at the VTEC 2015 Conference – The triennial International Symposium on Shiga Toxin (Verocytotoxin)-producing Escherichia coli (the VTEC Conference) was held in Boston from September 13th to 16th, 2015. Approximately 300 researchers in epidemiology, infectious diseases, microbiology, immunology, veterinary sciences, pediatric nephrology and gastroenterology shared their latest...
Read More

Share this

Sign up for email alerts

Email Address *